Skip to content

Short Term Follow-up of Patient Implanted With the Metatarso-Phalangeal Prosthesis METIS®

Short Term Follow-up of Patient Implanted With the Metatarso-Phalangeal Prosthesis METIS®

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01284985
Enrollment
60
Registered
2011-01-27
Start date
2009-02-28
Completion date
2013-07-31
Last updated
2014-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hallux Limitus, Hallux Rigidus, Hallux Valgus, Osteoarthritis, Rheumatoid Arthritis - Ankle and/or Foot

Brief summary

The great toe is vital for normal, pain free ambulation. Decreased function associated with osteoarthritis of the first matatarsal phalangeal joint (MTP I) often called Hallux Rigidis or Hallux Limitus leading to a painful great toe. Patients experience pain during ambulation especially during the push-off phase of gait. When surgery is indicated four techniques are used for hallux rigidis; cheilectomie, resection arthroplasty, arthrodesis and implant surgery (1). Endoprostetic implants are relatively new. Silicone Implants like the arthroplasty developed by Swanson (2) resulted in foreign body reactions and periarticular bone loss. Subsequent implants, in particular the metallic hemi arthroplasty with or without polyethylene articulations, have been more successful (3). Still, implants are prone to wear of the material and show higher rates of loosening and infection compared to other techniques (4;5). In the last decades several new implants are described using two non cemented pressfit components, of titanium alloy or ceramic (6-9). Between 2001 and 2004 the investigators developed a new concept with instrumentation for exact alignment to prevent for wear with loosening of the implant on the long term. The implant has bone-conserving characteristics to enable arthrodesis as a salvage procedure. It is a completely modular two-component press fit titanium alloy implant with polyethylene insert that can be used as either for hemi-, total- or revision arthroplasty. The purpose of this study is to have an overview of clinical status of the patient implanted with the METIS® prosthesis at short term (2 years of follow-up). The objective of this study is to evaluate the safety and efficacy of the Metatarso-Phalangeal prosthesis METIS® at short term follow up.

Interventions

None listed

Sponsors

Integra LifeSciences Services
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years; * Have willingness to give his/her data transfer authorisation; * has an indication of: Hallux Rigidus, Hallux Limitus with degenerative joint disease, Painful Hallux Valgus, Osteoarthritis, Rheumatoid arthritis, Post-traumatic arthritis, for which surgeon has recommended that a METIS® prosthesis be implanted

Exclusion criteria

* active infection or inflammation; * excessive bone loss, bone deficiency or rapid joint destruction; * suspected or documented metal allergy or intolerance; * metatarsal head or phalangeal avascular necrosis; * joint instability involving soft and fibrous tissue deficiency; * severe metatarso-phalangeal axis deviation (Hallux Valgus angle \> 20°); * prior mental illness or patient demonstrates that their mental capacity may interfere with their ability to follow the study protocol; * a previous joint replacement.

Design outcomes

Primary

MeasureTime frame
occurrence of device related complicationsat 2 years

Secondary

MeasureTime frame
improvement of the AOFAS Hallux Metatarsophalangeal-Interphalangeal Scale (HMIS) score (American Orthopaedic Foot and Ankle Society)at 2 year
Device related complications1 year
AOFAS HMIS score1 year
Quality of Life scoreovertime
X-ray evaluationovertime

Countries

Czechia, Netherlands, South Africa, Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026